Skip to main content

Longitudinal study of correlates of immunity to tuberculosis in exposed individuals

Objective

Tuberculosis causes 2-3 million deaths/year. A more effective vaccine than BCG is required, but rational vaccine trials cannot be planned for two main reasons. First, although many mycobacterium antigens have been isolated, we do not know which ones to test in human trials. It is not possible to test them all. Secondly we do not know which mechanisms are crucial for killing M. tuberculosis in man, so we cannot rationally select an adjuvant, or plan short term pilot studies using surrogate markers of protection. VACSEL will therefore conduct longitudinal studies, in 3 geographically distinct African countries, of TB contacts who do or do not develop clinical disease, in order to identify ;
i) the antigens,
ii) the cytokine profile and
iii) the markers of apoptosis, that correlate with protection so that rational design and testing of vaccines can begin.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

UNIVERSITY COLLEGE LONDON
Address
46 Cleveland Street
W1P 6DB London
United Kingdom

Participants (4)

ARMAUER HANSEN RESEARCH INSTITUTE
Ethiopia
Address
1005
2003 Addis Abeba
MEDICAL RESEARCH COUNCIL
The Gambia
Address
Atlantic Road Mrc Laboratories Fajara
20 Banjul
STATENS SERUM INSTITUT
Denmark
Address
5,Artillerivej 5
2300 Koepenhagen
UNIVERSITY OF ZAMBIA
Zambia
Address
University Teaching Hospital "D" Block, Jaoaranda
10100 Lusaka